AKERS: Big upturn available.

Monday, Mar 07 2011 by
1

Game changer
Penny has a strong track record of picking winners from the healthcare and diagnostics market and he sees the near-term prospect of cash generation from the Heparin PF4 product.

This test screens for allergies to a widely used blood thinner, Heparin, which affects some 12 million people in the US. The study for this will commence within the next two to three months and Penny is excited about its prospects.

Last week, Citywire AAA-rated Penny doubled his stake from 14,000 to 28,035,000 shares in the group, taking his ownership of the company to 16.61%.

Penny has none in his L&G UK Alpha Trust as a minimum stake in there would need to be around 4%, but he has put the stock into his life product equivalent.

Akers is currently trading at 3.75p but its broker Daniel Stewart has upgraded its target price from 6p to 10p and calculates some 82% upside following the placing.

Penny told Citywire: ‘There is enough there to make this exciting. They have some products with big potential and are funded for the next 12 months.

Penny tips the Heparin allergy testing product to bring in near-term cash. Indeed, it could be the 'game changer', he says.


Disclaimer:  

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. The author may own shares in any companies discussed, all opinions are his/her own & are general/impersonal. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.


Do you like this Post?
Yes
No
1 thumb up
0 thumbs down
Share this post with friends



Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company’s primary focus is the development and sale of the disposal diagnostic testing devices to facilitate time sensitive therapeutic decisions. The Company’s main products are a disposal breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposal breathalyzer test that measures free radical activity in the human body. The Company’s products include BreathScan, BreathScan PRO, METRON, VIVO, Heparin/PF4 Antibody Serum Panels, and Breath Ketone. more »

Share Price (AIM)
260p
Change
0.0  0.0%
P/E (fwd)
n/a
Yield (fwd)
n/a
Mkt Cap (£m)
13.3



  Is Akers Biosciences Inc fundamentally strong or weak? Find out More »


1 Post on this Thread show/hide all

shareshark23 11th Apr '11 1 of 1

this share is going from strength to strength....... the final results give a great insight into all the products and the financials are improving dramatically.

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=10837326

| Link | Share

What's your view on this thread? to Comment Now

 
 
You are feeling neutral

Use the £ sign in front of a ticker to turn £VOD into Vodafone PLC

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre



Stock Picking Simplified

Stockopedia takes your stock picking to the next level with cutting edge Stock Reports & Screening tools.


Get started
or Take a Tour to find out more.